Stockreport

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA ...

ImmunityBio, Inc.  (IBRX) 
PDF The QUILT-2.005 randomized clinical trial is on track for final analysis and supplemental Biologics License Application (BLA) submission in 2026 for the BCG-naïve NMIBC [Read more]